The Convergence of Science and Hope

At Argos, we believe in the power of human potential. To this end, we’re leading the way in personalized immunotherapy to deliver next generation treatments that fully recognize disease and engage the body to fight—treatments that will one day conquer cancer and other diseases. With each breakthrough we build momentum, offering more reason to stand behind Argos and our efforts to eradicate diseases, one patient at a time.

View the Arcelis Platform

Argos in The News

Argos Therapeutics Reports Third Quarter 2015 Financial Results and Operational Highlights
Read more

Argos Therapeutics to Host Third Quarter 2015 Financial Results Conference Call on Monday, November 16, 2015
Read more

Argos Therapeutics to Participate in 3rd Annual EU Advanced Therapies Investor Day
Read more

> More News & Events Here.

1999

When Our Company Was Founded

2006

First Arcelis product (AGS-003) clinical trial initiated in mRCC

2013

Phase 3 mRCC ADAPT Study Launched

180

Newly diagnosed RCC patients daily in the US, of which ~ 30 will present with stage IV or metastatic RCC